NCT06220552: The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
- State
- Under way
- Phase
- Phase 2
- People
- 20 planned
- Started
- 27 Dec 2023
- Primary completion
- 30 Dec 2027
- Arms
- Low-dose Radiotherapy Combined With Sintilimab and Temozolomide
- Results
- None posted
- 27 Dec 2023: Trial started
- 24 Jan 2024: Trial registered